Myriad Genetics (NASDAQ:MYGN) Issues Earnings Results, Beats Expectations By $0.06 EPS

Myriad Genetics (NASDAQ:MYGN) issued its earnings results on Monday. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.06, FiscalAI reports. The business had revenue of $209.80 million during the quarter, compared to analyst estimates of $207.57 million. Myriad Genetics had a negative return on equity of 7.11% and a negative net margin of 48.53%.The firm’s revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.03 EPS.

Here are the key takeaways from Myriad Genetics’ conference call:

• Q4 results beat guidance with revenue of $209.8M (FY2025 $824.5M), ~70% adjusted gross margin, $14.3M adjusted EBITDA and adjusted EPS of $0.04.
• Commercial momentum in core tests: MyRisk volumes grew 14% (affected) / 11% (unaffected) in Q4, Prolaris volume was up 12% (revenue +16%), and GeneSight volume grew 9%, driven by EMR integration and expanded commercial effort.
• Pipeline catalysts underway — alpha commercial testing of Precise MRD for breast cancer begins next week (limited centers), plus planned 2026 launches of an AI‑enabled Prolaris test and the FirstGene prenatal screen, with MolDx submissions targeted later in 2026.
• Near‑term headwinds include a ~$8.1M Q4 impact from UnitedHealthcare’s GeneSight policy, ~190 bps YoY ASP pressure, a Q2 order‑management disruption that hurt prenatal volumes (Q1 2026 prenatal expected to decline), and uncertain MolDx timing that could delay MRD reimbursement; management expects little‑to‑no MRD revenue in 2026.
• Outlook and investment: management reaffirmed 2026 guidance of $860M–$880M revenue and $37M–$49M adjusted EBITDA, plans to invest >$35M over the next few years to expand commercial/medical headcount and is reorganizing reporting around a cancer care continuum focus.

Myriad Genetics Stock Performance

MYGN stock opened at $4.38 on Tuesday. The firm has a market cap of $408.26 million, a PE ratio of -1.01 and a beta of 1.90. The company has a quick ratio of 2.12, a current ratio of 2.33 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average of $5.78 and a 200-day moving average of $6.64. Myriad Genetics has a 12-month low of $3.76 and a 12-month high of $14.73.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MYGN. Zacks Research downgraded Myriad Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday, December 29th. UBS Group upped their price objective on shares of Myriad Genetics from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Piper Sandler dropped their price objective on shares of Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Finally, TD Cowen reissued a “hold” rating on shares of Myriad Genetics in a research report on Tuesday, November 4th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.44.

Key Stories Impacting Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Q4 results: Myriad reported results that many outlets called a beat — revenue roughly $209.8M and reported EPS above consensus (company and some outlets highlighted the upside), which drove initial upside in the stock. Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Q1 revenue outlook: Management sees Q1 revenue rising about 2%–4% year-over-year, signaling near-term growth and supporting the rally. Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y
• Positive Sentiment: Reiterated FY2026 guidance: The company reiterated full-year 2026 guidance and highlighted execution improvements and better operating cash flow, which supports investor confidence. Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance
• Neutral Sentiment: Analyst nuance: TD Cowen stayed at Hold with a $7 target, highlighting valuation merits but ongoing uncertainty — a reminder the narrative is mixed among analysts. Balancing Emerging Growth Momentum and Ongoing Uncertainty: Justifying a Hold
• Neutral Sentiment: Read the call/metrics: Transcripts, slide deck and analyst notes (Zacks, Seeking Alpha) provide the details investors should check to reconcile GAAP vs. adjusted metrics and to see segment-level trends. Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Sell reiteration: Bank of America reaffirmed a Sell rating with a $4 price target, citing execution and reimbursement risks that could restrain longer-term growth — a key bearish catalyst that may cap upside. Execution and Reimbursement Risks Undermine Myriad Genetics’ Growth Outlook
• Negative Sentiment: Mixed/weak quarter metrics flagged by some outlets: Certain reports highlighted narrower operating results, GAAP losses or metric discrepancies (driving confusion over the quarter) — these items could prompt profit-taking or caution among institutional holders. Myriad Genetics (MYGN) Stock Falls on Q4 2025 Earnings

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MYGN. Alliancebernstein L.P. increased its position in shares of Myriad Genetics by 1.8% during the 3rd quarter. Alliancebernstein L.P. now owns 101,234 shares of the company’s stock valued at $732,000 after purchasing an additional 1,784 shares during the last quarter. Legal & General Group Plc grew its position in Myriad Genetics by 1.0% during the second quarter. Legal & General Group Plc now owns 237,688 shares of the company’s stock valued at $1,262,000 after buying an additional 2,313 shares during the period. Quarry LP increased its holdings in Myriad Genetics by 155.6% during the fourth quarter. Quarry LP now owns 4,365 shares of the company’s stock worth $27,000 after buying an additional 2,657 shares during the last quarter. Franklin Resources Inc. increased its holdings in Myriad Genetics by 2.7% during the fourth quarter. Franklin Resources Inc. now owns 103,374 shares of the company’s stock worth $636,000 after buying an additional 2,714 shares during the last quarter. Finally, Royal Bank of Canada raised its position in Myriad Genetics by 129.6% in the fourth quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock worth $31,000 after acquiring an additional 2,818 shares during the period. Institutional investors own 99.02% of the company’s stock.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.